ExpreS2ion Biotech associated company AdaptVac, in which ExpreS2ion owns 34 percent, is leading a consortium awarded USD 12,4 million (approximately SEK 115 million) from CEPI and The EU's Horizon Europe programThe non-dilutive funding supports the development of a vaccine against multiple deadly filoviruses including Ebola and Marburg. The five-year project includes planned Phase I/II studies in Gabon and the Netherlands.
AdaptVac awarded SEK 115 million for filovirus vaccine
Notes
Cantargia publishes data for nadunolimab in lung cancer
Genmab reports sales of DARZALEX
AlzeCure receives additional subscription commitments of SEK 7 million
AstraZeneca updates on phase III study
Orexo maintains full-year forecast despite currency headwinds
BioGaia launches subsidiary for microbiome research
Isofol receives positive FDA feedback for arfolitixorin
NEWSLETTER
Upcoming events
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Recommended
Trump threatens 200 percent tariffs on pharmaceuticals
AbbVie acquires Capstan Therapeutics for up to $2,1 billion
GLP-1 drugs drive pharmaceutical boom to 2030
FDA introduces fast track for drugs of national importance
Monetization of future royalties increasingly popular
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
